Prophylactic IFN-γ blockade drives axi-cel expansion without preventing refractory toxicities: caution against pre-emptive use. (PubMed, Blood Cancer Discov) - Oct 20, 2026 - P2 | "We initiated an open-label phase 2 trial (NCT06550141) evaluating single-dose emapalumab one day before axi-cel. Both patients achieved complete responses, suggesting preserved efficacy. Given the unanticipated severity and refractoriness of toxicities, recruitment with this design was discontinued and the protocol was amended."
Journal • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • IFNG • IL2
|
|
Alexandra M Haugh; Benjamin R Puliafito; David J Bozym; Deshea L Harris; Elliot C Woods; Jacob D Soumerai; Jeremy S Abramson; Jing Li; Julie E Haydu; Kathleen Me Gallagher; Keshav Sridharan; Marcela V Maus; Marisa G Ogier; Mark B Leick; Matthew J Frigault; Maxx King; Patrick C Johnson; Viktoria Blumenberg; Yi-Bin Chen
|